Market research
4883.TSE Modalis Therapeutics Corporation
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 900
- Dividend yield
- Not available
- Beta
- 0.4
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3922600006
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 900
- Dividend yield
- Not available
- Beta
- 0.4
About
About Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the 4883.TSE discussion.
No comments yet
Start a focused discussion about 4883.TSE.